Informative noncompliance in endpoint trials

Current Controlled Trials in Cardiovascular Medicine

Volumn 5, Issue , 2004, Pages

  Snapinn, Steven M ^a   Jiang, Qi ^b   Iglewicz, Boris ^c  

^a AMGEN INC   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c TEMPLE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; CAPTOPRIL; ENALAPRIL; LOSARTAN; PLACEBO;

CALCULATION; CLINICAL TRIAL; DATA ANALYSIS; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; KIDNEY DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; REVIEW; RISK ASSESSMENT; SAMPLE SIZE; STATISTICAL ANALYSIS;

EID: 4444374619     PISSN: 14686694     EISSN: 14686694     Source Type: Journal    
DOI: 10.1186/1468-6708-5-5     Document Type: Review

References (22)

1. ISIS-4 Collaborative Group: A randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulfate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995, 345:669-685.
2. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981-2997.
3. Medical Research Council Working Party: MRC trial of treatment of mild hypertension: principal results. Br Med J 1985, 291:97-104.
4. MRC Working Party: Medical research council trial of treatment of hypertension in older adults: principal results. Br Med J 1992, 304:405-412.
5. Jiang Q, Snapinn S, Iglewicz B: Sample size adjustment in survival data. In Encyclopedia of Biopharmaceutical Statistics 2nd edidon. New York: Marcel Dekker, Inc; 2003:892-898.
6. Halperin M, Rogot E, Curian J, Ederer F: Sample sizes for medical trials with special reference to long-term therapy. J Chronic Dis 1968, 21:13-24.
7. Wu M, Fisher M, DeMets D: Sample sizes for long-term medical trial with time-dependent dropout and event rates. Control Clin Trials 1980, 1:111-123.
8. Freedman LS: Tables of the number of patients required in clinical trials using the logrank test. Stat Med 1982, 1:121-129.
9. Lachin JM, Foulkes MA: Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. Biometrics 1986, 12:507-519.
10. Lakatos E: Sample size determination in clinical trials with time-dependent rates of losses and noncompliance. Control Clin Trials 1986, 7:189-199.
11. Lakatos E: Sample sizes based on the logrank statistic in complex clinical trials. Biometrics 1988, 44:229-241.
12. Robins JM, Tsiatis AA: Correcting for noncompliance in randomized trials using rank preserving structural failure time models. Communications in Statistics A 1991, 20(8):2609-2631.
13. Robins JM: Marginal structural models versus structural nested models as tools for causal inference. In Statistical Models in Epidemiology: The Environment and Clinical Trials Edited by: Halloran ME, Berry D. New York: Springer-Verlag; 1999.
14. Loeys T, Goeighebeui E: A causal proportional hazards estimator for the effect of treatment actually received in a randomized trial with all-or-nothing compliance. Biometrics 2003, 59:100-105.
15. Lachin JM: Statistical considerations in the intent-to-treat principle. Control Clin Trials 2000, 21:167-189.
16. Snapinn SM, Jiang Q, Iglewicz B: Illustrating the impact of a time-varying covariate with an extended Kaplan-Meier estimator. 1 unpublished manuscript.
17. The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991, 325:293-302.
18. The SOLVD Investigators: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction. N Engl J Med 1992, 327:685-691.
19. Brenner BM, Cooper ME, de Zeeuw D, et al.: Effects of losartan on renal and cardiovascular outcomes in patients type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869.
20. Dahlöf B, Devereux RB, Kjeldsen SE, et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995-1003.
21. Dickstein K, Kjekshus J, the OPTIMAAL Steering Committee, for the OPTIMAAL Study Group: Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 2002, 360:752-760.
22. Jiang Q, Snapinn S, Iglewicz B: Calculation of sample size in survival trials: the impact of informative noncompliance. Biometrics 2004, 60:800-806.